PortalPublikationenImpact of a compliance program on cholesterol control: resul...

Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin.

Standard

Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. / Willich, Stefan N; Englert, Heike; Sonntag, Frank; Völler, Heinz; Meyer-Sabellek, Wolfgang; Wegscheider, Karl; Windler, Eberhard; Katus, Hugo; Müller-Nordhorn, Jacqueline.

in: EUR J CARDIOV PREV R, Jahrgang 16, Nr. 2, 2, 2009, S. 180-187.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Willich, SN, Englert, H, Sonntag, F, Völler, H, Meyer-Sabellek, W, Wegscheider, K, Windler, E, Katus, H & Müller-Nordhorn, J 2009, 'Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin.', EUR J CARDIOV PREV R, Jg. 16, Nr. 2, 2, S. 180-187. <http://www.ncbi.nlm.nih.gov/pubmed/19174696?dopt=Citation>

APA

Willich, S. N., Englert, H., Sonntag, F., Völler, H., Meyer-Sabellek, W., Wegscheider, K., Windler, E., Katus, H., & Müller-Nordhorn, J. (2009). Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. EUR J CARDIOV PREV R, 16(2), 180-187. [2]. http://www.ncbi.nlm.nih.gov/pubmed/19174696?dopt=Citation

Vancouver

Willich SN, Englert H, Sonntag F, Völler H, Meyer-Sabellek W, Wegscheider K et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. EUR J CARDIOV PREV R. 2009;16(2):180-187. 2.

Bibtex

@article{47c041d4a58d43588e2a8a54288e2bc4,
title = "Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin.",
abstract = "AIM: To determine whether a compliance-enhancing program could increase the level of lipid control in patients treated with rosuvastatin. METHODS AND RESULTS: A total of 8108 patients (56% men, mean age 59 years; 44% women, mean age 63 years) with low-density lipoprotein cholesterol (LDL-C) >or=115 mg/dl if statin-naive or else >or=125 mg/dl were randomized to rosuvastatin 10 mg daily either with or without a compliance-enhancing program for 12 months. Patients not achieving the goal after 3 months were uptitrated to rosuvastatin 20 mg daily thereafter. At 3, 6, and 12 months, rosuvastatin plus compliance initiatives were similarly effective to rosuvastatin alone in terms of 1998 European LDL-C goal of less than 115 mg/dl achievement (72 vs. 70%, 71 vs. 69%, 68 vs. 68%) and changes in the lipid profile. Significant differences were observed in the subgroup of statin-naive patients at 3 and 6 months (80 vs. 76% and 78 vs. 73%, P",
author = "Willich, {Stefan N} and Heike Englert and Frank Sonntag and Heinz V{\"o}ller and Wolfgang Meyer-Sabellek and Karl Wegscheider and Eberhard Windler and Hugo Katus and Jacqueline M{\"u}ller-Nordhorn",
year = "2009",
language = "Deutsch",
volume = "16",
pages = "180--187",
journal = "EUR J PREV CARDIOL",
issn = "2047-4873",
publisher = "SAGE Publications",
number = "2",

}

RIS

TY - JOUR

T1 - Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin.

AU - Willich, Stefan N

AU - Englert, Heike

AU - Sonntag, Frank

AU - Völler, Heinz

AU - Meyer-Sabellek, Wolfgang

AU - Wegscheider, Karl

AU - Windler, Eberhard

AU - Katus, Hugo

AU - Müller-Nordhorn, Jacqueline

PY - 2009

Y1 - 2009

N2 - AIM: To determine whether a compliance-enhancing program could increase the level of lipid control in patients treated with rosuvastatin. METHODS AND RESULTS: A total of 8108 patients (56% men, mean age 59 years; 44% women, mean age 63 years) with low-density lipoprotein cholesterol (LDL-C) >or=115 mg/dl if statin-naive or else >or=125 mg/dl were randomized to rosuvastatin 10 mg daily either with or without a compliance-enhancing program for 12 months. Patients not achieving the goal after 3 months were uptitrated to rosuvastatin 20 mg daily thereafter. At 3, 6, and 12 months, rosuvastatin plus compliance initiatives were similarly effective to rosuvastatin alone in terms of 1998 European LDL-C goal of less than 115 mg/dl achievement (72 vs. 70%, 71 vs. 69%, 68 vs. 68%) and changes in the lipid profile. Significant differences were observed in the subgroup of statin-naive patients at 3 and 6 months (80 vs. 76% and 78 vs. 73%, P

AB - AIM: To determine whether a compliance-enhancing program could increase the level of lipid control in patients treated with rosuvastatin. METHODS AND RESULTS: A total of 8108 patients (56% men, mean age 59 years; 44% women, mean age 63 years) with low-density lipoprotein cholesterol (LDL-C) >or=115 mg/dl if statin-naive or else >or=125 mg/dl were randomized to rosuvastatin 10 mg daily either with or without a compliance-enhancing program for 12 months. Patients not achieving the goal after 3 months were uptitrated to rosuvastatin 20 mg daily thereafter. At 3, 6, and 12 months, rosuvastatin plus compliance initiatives were similarly effective to rosuvastatin alone in terms of 1998 European LDL-C goal of less than 115 mg/dl achievement (72 vs. 70%, 71 vs. 69%, 68 vs. 68%) and changes in the lipid profile. Significant differences were observed in the subgroup of statin-naive patients at 3 and 6 months (80 vs. 76% and 78 vs. 73%, P

M3 - SCORING: Zeitschriftenaufsatz

VL - 16

SP - 180

EP - 187

JO - EUR J PREV CARDIOL

JF - EUR J PREV CARDIOL

SN - 2047-4873

IS - 2

M1 - 2

ER -